Headquarters: Copenhagen, Denmark
CEO: Mr. Ole Thastrup VD
EUR as of July 1, 2023
|Company||Market Cap (USD)|
|Novo Nordisk||$329.83 B|
|Vertex Pharmaceuticals Incorporated||$88.79 B|
|CSL Limited||$85.00 B|
|Marinomed Biotech AG||$84.73 B|
|Regeneron Pharmaceuticals, Inc.||$78.88 B|
2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat test that allows the physician to identify a medical treatment that is effective for a particular cancer patient. IndiTreat establishes thousands of 3D micro-tumors that are similar to the patient's tumor and identifies the treatment that kills the patient's tumor. The company is also conducting various clinical programs for IndiTreat for colorectal, ovarian, and pancreatic cancers. 2cureX AB has clinical partnerships with Skåne University Hospital in Sweden; and University Medical Center Hamburg-Eppendorf. The company was incorporated in 2006 and is based in Copenhagen, Denmark.
Unlock the Power of Financial AI:
Try Disfold AI Free for 7 Days!